2026年全球乳癌診斷市場報告

近年來，乳癌診斷市場成長顯著，預計到2025年將達到50億美元，到2026年將達到54.2億美元，複合年成長率為8.3%。過去幾年的成長可歸因於多種因素，例如全球乳癌率的上升、早期癌症篩檢意識提升、診斷影像基礎設施的擴展、生物標記檢測的日益普及以及切片檢查準確性和安全性的提高。

預計未來幾年乳癌診斷市場規模將強勁成長，2030年將達到72.8億美元，複合年成長率（CAGR）為7.7%。預測期內的成長可歸因於精準腫瘤診斷技術的日益普及、人工智慧診斷平台投資的增加、對微創檢測需求的成長、基於人群的篩檢項目的擴展以及分子診斷技術的持續進步。預測期內的關鍵趨勢包括人工智慧輔助影像分析的日益普及、基因組和分子檢測的廣泛應用、液態生物檢體技術的日益普及、先進的非電離輻射成像方式的擴展以及對早期和個性化診斷的日益重視。

乳癌診断市場は今後数年間、政府主導の乳癌対策および資金支援により成長が見込まれます。こうした施策は公衆衛生と経済発展に寄与するプログラムや計劃への財政的支援を提供します。これらの取り組みは、啓発活動の推進、検診や乳房X光攝影による早期発見の促進、医療サービスが行き届いていない地域への検査,治療費の財政的支援を通じて、乳癌の研究,予防,治療を支える重要な役割を果たしています。例えば、オーストラリア衛生署は2022-23年度予算において、各種がん検査,篩檢サービスのアクセス改善、COVID-19パンデミックによる遅延の解消、適切な紹介,迅速な診断,早期療育の実現に向け、4,070万豪ドルを配分しました。このうち970万豪ドルは乳癌検診に特化して充てられています。したがって、政府の取り組みと資金提供が乳癌診断市場の拡大を支えているのです。

乳癌診斷市場的主要企業正致力於人工智慧驅動的創新，旨在提高診斷準確性、簡化工作流程並支援個人化治療方案。基於人工智慧的診斷平台利用機器學習和深度學習演算法分析醫學影像、病理切片和臨床數據，從而提供洞察和風險分層，為臨床決策提供支援。例如，2024年9月，以色列數位病理公司Ibex Medical Analytics擴展了其乳癌診斷人工智慧平台，在其Ibex Breast HER2模組中引入了全自動、零點擊的HER2免疫組化（IHC）評分功能。該工具能夠識別浸潤性癌症區域並對HER2表達水平（0、1+、2+、3+）進行分類，以更高的準確性和工作流程效率支持乳癌的診斷和治療決策。

目錄

第1章執行摘要

第2章 市場特徵

• 市場定義和範圍
• 市場區隔
• 主要產品和服務概述
• 世界の乳癌診断市場：魅力度スコアと分析
• 成長潛力分析、競爭評估、策略契合度評估、風險狀況評估

第3章 市場供應鏈分析

• 供應鏈與生態系概述
• 主要原料、資源和供應商清單
• 主要經銷商和通路合作夥伴名單
• 主要最終用戶列表

第4章 全球市場趨勢與策略

• 關鍵技術和未來趨勢
  • 人工智慧（AI）和自主人工智慧
  • 生物技術、基因組學和精準醫學
  • 數位化、雲端運算、巨量資料、網路安全
  • 物聯網、智慧基礎設施和互聯生態系統
  • 工業4.0和智慧製造
• 主要趨勢
  • 人工智慧輔助影像分析的應用日益廣泛
  • ゲノム検査および分子検査の利用拡大
  • 液態生物檢體技術的應用日益廣泛
  • 擴展先進的非電離輻射成像方法
  • 越來越重視早期和個人化診斷

第5章 終端用戶產業市場分析

• 醫院和診所
• 診斷檢查室
• 癌症研究中心
• 門診手術中心
• 專科腫瘤診所

第6章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅的影響、關稅戰和貿易保護主義對供應鏈的影響，以及新冠疫情對市場的影響

第7章 全球策略分析架構、目前市場規模、市場對比及成長率分析

• 全球乳癌診斷市場：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
• 世界の乳癌診断市場規模、比較、成長率分析
• 全球乳癌診斷市場表現：規模與成長，2020-2025年
• 世界の乳癌診断市場の予測：規模と成長、2025年～2030年、2035年

第8章 全球潛在市場規模（TAM）

第9章 市場細分

• 按類型
• 画像診断、切片檢查、ゲノム検査、血液検査、その他のタイプ
• 透過技術
• 螢光in situ雜合反應（FISH）、比較ゲノム雜合反應（CGH）、免疫組織化学（IHC）、その他の技術
• 按癌症類型
• BRCA乳癌、ERおよびPR乳癌、HER2陽性乳癌、トリプルネガティブ乳癌、その他のがんタイプ
• 按診斷類型
• 利用電離輻射的乳房攝影診斷技術，利用非電離輻射的影像診斷技術
• 最終用戶
• 病院および診療所、がん研究センター、診断檢查室、外来手術センター
• 按類型細分：診斷成像
• 乳房超音波影像攝影、超音波影像、磁振造影（MRI）、正子斷層掃描（PET）、斷層合成影像
• 按類型細分：切片檢查
• 針吸切片、粗針穿刺切片、細針穿刺切片檢查（FNA）、立體定位切片檢查
• 按類型細分：基因組檢測
• Oncotype DX、MammaPrint、PAM50、BRCA1 或 BRCA2 檢測
• 按類型細分：血液檢測
• 液態生物檢體、循環腫瘤DNA（ctDNA）檢測、循環性腫瘤細胞（CTC）檢測
• 按類型細分：其他類型
• 荷爾蒙受體檢測、HER2檢測、基因突變檢測

第10章 區域與國家分析

• 世界の乳癌診断市場：地域別、実績と予測、2020年～2025年、2025年～2030年、2035年
• 世界の乳癌診断市場：国別、実績と予測、2020年～2025年、2025年～2030年、2035年

第11章 亞太市場

第12章：中國市場

第13章 印度市場

第14章 日本市場

第15章：澳洲市場

第16章 印尼市場

第17章 韓國市場

第18章 台灣市場

第19章 東南亞市場

第20章：西歐市場

第21章英國市場

第22章 德國市場

第23章：法國市場

第24章：義大利市場

第25章：西班牙市場

第26章 東歐市場

第27章：俄羅斯市場

第28章 北美市場

第29章：美國市場

第30章：加拿大市場

第31章 南美洲市場

第32章：巴西市場

第33章 中東市場

第34章：非洲市場

第35章 市場監理與投資環境

第36章：競爭格局與公司概況

• 乳癌診断市場：競合情勢と市場シェア、2024年
• 乳癌診斷市場：公司估值矩陣
• 乳癌診断市場：企業プロファイル
  • Abbott Laboratories
  • Myriad Genetics Inc.
  • Hologic Inc.
  • Koninklijke Philips NV
  • Fujifilm Holdings Corporation

第37章：其他領先和創新企業

• GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Dilon Technologies Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Micrima Limited, Provista Diagnostics Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc.

第38章 全球市場競爭基準分析與儀錶板

第39章 重大併購

第40章：高潛力市場國家、細分市場與策略

• 2030年乳癌診斷市場：提供新機會的國家
• 乳癌診断市場2030年：新たな機会を提供するセグメント
• 2030年乳癌診斷市場：成長策略
  • 基於市場趨勢的策略
  • 競爭對手策略

第41章附錄

Breast cancer is a medical condition characterized by the uncontrolled proliferation of cells within the breast, often leading to the formation of lumps. Breast cancer diagnostic devices are designed for the purpose of identifying and confirming the presence of cancerous growth within the breast tissue.

Key categories within breast cancer diagnostics include various diagnostic methods such as imaging techniques, biopsies, genomic testing, blood tests, and other relevant approaches. Biopsy, a process involving the removal of tissue or cellular samples from the body for subsequent laboratory testing, is one of the primary diagnostic techniques employed in breast cancer cases. The technologies utilized for these diagnostic procedures encompass Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC) techniques, along with others. Breast cancer exhibits diverse types, including BRCA breast cancer, ER and PR breast cancer, HER2-positive breast cancer, EGFR mutation test breast cancer, and additional variants. Breast cancer diagnostics are further categorized into ionizing breast imaging technologies and non-ionizing imaging technologies. The end-users of these diagnostic services encompass hospitals and clinics, cancer research centers, diagnostic laboratories, as well as ambulatory surgical centers.

Tariffs are impacting the breast cancer diagnostics market by increasing costs of imported imaging systems, genomic testing kits, reagents, biopsy devices, and advanced laboratory equipment. Diagnostic laboratories and hospitals in North America and Europe are most affected due to reliance on imported high-value diagnostic technologies, while Asia-Pacific faces cost pressures on equipment procurement and test consumables. These tariffs are raising operational costs and slowing technology upgrades in some healthcare facilities. However, they are also encouraging local manufacturing of diagnostic kits, regional reagent production, and domestic innovation in imaging and molecular testing solutions.

The breast cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides breast cancer diagnostics market statistics, including breast cancer diagnostics industry global market size, regional shares, competitors with a breast cancer diagnostics market share, detailed breast cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer diagnostics industry. This breast cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The breast cancer diagnostics market size has grown strongly in recent years. It will grow from $5 billion in 2025 to $5.42 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to rising incidence of breast cancer globally, increased awareness of early cancer screening, expansion of diagnostic imaging infrastructure, growing availability of biomarker-based tests, improvements in biopsy accuracy and safety.

The breast cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $7.28 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to increasing adoption of precision oncology diagnostics, rising investments in AI-enabled diagnostic platforms, growing demand for minimally invasive testing, expansion of population-based screening programs, continuous advancements in molecular diagnostic technologies. Major trends in the forecast period include increasing adoption of ai-assisted imaging analysis, rising use of genomic and molecular testing, growing deployment of liquid biopsy techniques, expansion of advanced non-ionizing imaging modalities, enhanced focus on early and personalized diagnosis.

Government initiatives and funding for breast cancer are expected to drive growth in the breast cancer diagnostics market in the coming years. Such initiatives provide financial support to programs or projects that contribute to public health and economic development. These efforts play a crucial role in supporting breast cancer research, prevention, and treatment by raising awareness, promoting early detection through screening and mammography, and offering financial assistance to underserved communities for testing and treatment. For example, in its 2022-23 budget, the Australian Government Department of Health allocated $40.7 million to improve accessibility to testing and screening services for various cancers, addressing setbacks caused by the COVID-19 pandemic, and enabling timely referrals, prompt diagnosis, and early intervention. Of this, $9.7 million was specifically dedicated to breast cancer screening. Therefore, government initiatives and funding are supporting the expansion of the breast cancer diagnostics market.

Major companies operating in the breast cancer diagnostics market are focusing on AI-driven innovations to improve diagnostic accuracy, streamline workflows, and support personalized treatment planning. AI-based diagnostic platforms use machine learning and deep-learning algorithms to analyze medical imaging, pathology slides, or clinical data, providing insights and risk stratifications that aid clinical decision-making. For instance, in September 2024, Ibex Medical Analytics, an Israel-based digital pathology company, expanded its AI platform for breast cancer diagnostics by introducing a fully automated zero-click HER2 immunohistochemistry (IHC) scoring feature in its Ibex Breast HER2 module. This tool identifies invasive cancer regions, classifies HER2 expression levels (0, 1+, 2+, 3+), and supports breast cancer diagnosis and treatment decisions with enhanced accuracy and workflow efficiency.

In July 2024, Hologic Inc., a US-based healthcare technology company, acquired Endomagnetics Ltd. for $310 million. This acquisition strengthens Hologic's breast surgery portfolio by integrating Endomag's wireless localization and lymphatic tracing solutions. Endomagnetics Ltd., based in the UK, provides advanced technologies for breast cancer diagnostics, including tissue localization and lymphatic mapping solutions.

Major companies operating in the breast cancer diagnostics market are Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Dilon Technologies Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Micrima Limited, Provista Diagnostics Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc., Biocept Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Cepheid, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Oncocyte Corporation, PerkinElmer Inc., Sysmex Corporation, Veracyte Inc.

North America was the largest region in the breast cancer diagnostics market in 2025. Asia-Pacific was the second largest region in the breast cancer diagnostics industry. The regions covered in the breast cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the breast cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The breast cancer diagnostics market consists of sales of instruments such as analyzer, reagents and others that are used for the diagnosis of breast cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Breast Cancer Diagnostics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses breast cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for breast cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The breast cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Imaging; Biopsy; Genomic Tests; Blood Tests; Other Types
• 2) By Technology: Fluorescent In Situ Hybridization (FISH); Comparative Genomic Hybridization (CGH); Immunohistochemical (IHC); Other Technologies
• 3) By Cancer Type: BRCA Breast Cancer; ER And PR Breast Cancer; HER 2 Breast Cancer; Triple-Negative Breast Cancer; Other Cancer Types
• 4) By Diagnostic Type: Ionizing Breast Imaging Technologies; Non-ionizing Imaging Technologies
• 5) By End Users: Hospitals And Clinics; Cancer Research Centers; Diagnostic Laboratories; Ambulatory Surgical Centers
• Subsegments:
• 1) By Imaging: Mammography; Ultrasound Imaging; Magnetic Resonance Imaging (MRI); Positron Emission Tomography (PET); Tomosynthesis
• 2) By Biopsy: Needle Biopsy; Core Needle Biopsy; Fine Needle Aspiration Biopsy (FNA); Stereotactic Biopsy
• 3) By Genomic Tests: Oncotype DX; MammaPrint; PAM50; BRCA1 Or 2 Testing
• 4) By Blood Tests: Liquid Biopsy; Circulating Tumor DNA (ctDNA) Tests; Circulating Tumor Cells (CTCs) Tests
• 5) By Other Types: Hormone Receptor Tests; HER2 Tests; Genetic Mutation Testing
• Companies Mentioned: Abbott Laboratories; Myriad Genetics Inc.; Hologic Inc.; Koninklijke Philips N.V.; Fujifilm Holdings Corporation; GE Healthcare; Thermo Fisher Scientific Inc.; Siemens AG; NanoString Technologies Inc.; Gamma Medica Inc.; Aurora Imaging Technology Inc.; Dilon Technologies Inc.; Exact Sciences Corporation; F. Hoffmann-La Roche Ltd.; Micrima Limited; Provista Diagnostics Inc.; Leica Biosystems Nussloch GmbH; bioTheranostics Inc.; Bio-Rad Laboratories Inc.; Illumina Inc.; Biocept Inc.; Quest Diagnostics Incorporated; Agilent Technologies Inc.; Cepheid; Guardant Health Inc.; Invitae Corporation; Natera Inc.; NeoGenomics Laboratories Inc.; Oncocyte Corporation; PerkinElmer Inc.; Sysmex Corporation; Veracyte Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Breast Cancer Diagnostics Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Breast Cancer Diagnostics Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Breast Cancer Diagnostics Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Breast Cancer Diagnostics Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Artificial Intelligence & Autonomous Intelligence
  • 4.1.2 Biotechnology, Genomics & Precision Medicine
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.1.5 Industry 4.0 & Intelligent Manufacturing
• 4.2. Major Trends
  • 4.2.1 Increasing Adoption Of Ai-Assisted Imaging Analysis
  • 4.2.2 Rising Use Of Genomic And Molecular Testing
  • 4.2.3 Growing Deployment Of Liquid Biopsy Techniques
  • 4.2.4 Expansion Of Advanced Non-Ionizing Imaging Modalities
  • 4.2.5 Enhanced Focus On Early And Personalized Diagnosis

5. Breast Cancer Diagnostics Market Analysis Of End Use Industries

• 5.1 Hospitals And Clinics
• 5.2 Diagnostic Laboratories
• 5.3 Cancer Research Centers
• 5.4 Ambulatory Surgical Centers
• 5.5 Specialty Oncology Clinics

6. Breast Cancer Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Breast Cancer Diagnostics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Breast Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Breast Cancer Diagnostics Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Breast Cancer Diagnostics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Breast Cancer Diagnostics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Breast Cancer Diagnostics Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Breast Cancer Diagnostics Market Segmentation

• 9.1. Global Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Imaging, Biopsy, Genomic Tests, Blood Tests, Other Types
• 9.2. Global Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies
• 9.3. Global Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• BRCA Breast Cancer, ER And PR Breast Cancer, HER 2 Breast Cancer, Triple-Negative Breast Cancer, Other Cancer Types
• 9.4. Global Breast Cancer Diagnostics Market, Segmentation By Diagnostic Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Ionizing Breast Imaging Technologies, Non-ionizing Imaging Technologies
• 9.5. Global Breast Cancer Diagnostics Market, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals And Clinics, Cancer Research Centers, Diagnostic Laboratories, Ambulatory Surgical Centers
• 9.6. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Imaging, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Mammography, Ultrasound Imaging, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Tomosynthesis
• 9.7. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Biopsy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Needle Biopsy, Core Needle Biopsy, Fine Needle Aspiration Biopsy (FNA), Stereotactic Biopsy
• 9.8. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Genomic Tests, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oncotype DX, MammaPrint, PAM50, BRCA1 Or 2 Testing
• 9.9. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Blood Tests, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Liquid Biopsy, Circulating Tumor DNA (ctDNA) Tests, Circulating Tumor Cells (CTCs) Tests
• 9.10. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hormone Receptor Tests, HER2 Tests, Genetic Mutation Testing

10. Breast Cancer Diagnostics Market Regional And Country Analysis

• 10.1. Global Breast Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Breast Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Breast Cancer Diagnostics Market

• 11.1. Asia-Pacific Breast Cancer Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Breast Cancer Diagnostics Market

• 12.1. China Breast Cancer Diagnostics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Breast Cancer Diagnostics Market

• 13.1. India Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Breast Cancer Diagnostics Market

• 14.1. Japan Breast Cancer Diagnostics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Breast Cancer Diagnostics Market

• 15.1. Australia Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Breast Cancer Diagnostics Market

• 16.1. Indonesia Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Breast Cancer Diagnostics Market

• 17.1. South Korea Breast Cancer Diagnostics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Breast Cancer Diagnostics Market

• 18.1. Taiwan Breast Cancer Diagnostics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Breast Cancer Diagnostics Market

• 19.1. South East Asia Breast Cancer Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Breast Cancer Diagnostics Market

• 20.1. Western Europe Breast Cancer Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Breast Cancer Diagnostics Market

• 21.1. UK Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Breast Cancer Diagnostics Market

• 22.1. Germany Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Breast Cancer Diagnostics Market

• 23.1. France Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Breast Cancer Diagnostics Market

• 24.1. Italy Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Breast Cancer Diagnostics Market

• 25.1. Spain Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Breast Cancer Diagnostics Market

• 26.1. Eastern Europe Breast Cancer Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Breast Cancer Diagnostics Market

• 27.1. Russia Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Breast Cancer Diagnostics Market

• 28.1. North America Breast Cancer Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Breast Cancer Diagnostics Market

• 29.1. USA Breast Cancer Diagnostics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Breast Cancer Diagnostics Market

• 30.1. Canada Breast Cancer Diagnostics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Breast Cancer Diagnostics Market

• 31.1. South America Breast Cancer Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Breast Cancer Diagnostics Market

• 32.1. Brazil Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Breast Cancer Diagnostics Market

• 33.1. Middle East Breast Cancer Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Breast Cancer Diagnostics Market

• 34.1. Africa Breast Cancer Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Breast Cancer Diagnostics Market Regulatory and Investment Landscape

36. Breast Cancer Diagnostics Market Competitive Landscape And Company Profiles

• 36.1. Breast Cancer Diagnostics Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Breast Cancer Diagnostics Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Breast Cancer Diagnostics Market Company Profiles
  • 36.3.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Myriad Genetics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Hologic Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Koninklijke Philips N.V. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Fujifilm Holdings Corporation Overview, Products and Services, Strategy and Financial Analysis

37. Breast Cancer Diagnostics Market Other Major And Innovative Companies

• GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Dilon Technologies Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Micrima Limited, Provista Diagnostics Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc.

38. Global Breast Cancer Diagnostics Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Breast Cancer Diagnostics Market

40. Breast Cancer Diagnostics Market High Potential Countries, Segments and Strategies

• 40.1 Breast Cancer Diagnostics Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Breast Cancer Diagnostics Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Breast Cancer Diagnostics Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer